Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Net loss	$ (156,730)	$ (107,431)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	34,244	18,822
Depreciation on property and equipment	126	65
Non-cash lease expense	1,106	933
Other non-cash items	0	(282)
Changes in operating assets and liabilities:
Accounts receivable	(11,633)	(596)
Prepaid expenses and other current assets	2,137	753
Income tax receivable	(85)	(512)
Accounts payable	16,254	1,251
Accrued expenses	9,472	4,468
Operating lease liabilities	(1,179)	(798)
Due to Roivant Sciences Ltd.	176	0
Net cash used in operating activities	(106,112)	(83,327)
Cash flows from investing activities
Purchases of property and equipment	(254)	(210)
Net cash used in investing activities	(254)	(210)
Cash flows from financing activities
Capital contributions	129	1,096
Proceeds from stock options exercised	0	907
Payment of deferred offering costs	0	(1,236)
Net cash provided by financing activities	200,129	383,112
Effect of exchange rate changes on cash	(92)	0
Net change in cash	93,671	299,575
Cash – beginning of period	400,146	100,571
Cash – end of period	493,817	400,146
Non-cash operating activity
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	127	4,215
Supplemental disclosure of cash paid:
Income taxes	0	166
Underwritten Public Offering
Cash flows from financing activities
Proceeds from issuance of common stock	0	319,783
Warrant Redemption
Cash flows from financing activities
Proceeds from issuance of common stock	0	65,752
Roivant Sciences Ltd. (RSL)
Cash flows from financing activities
Proceeds from issuance of common stock	200,000	0
Repayment of note payable to Roivant Sciences Ltd.	$ 0	$ (3,190)